FLETCHER R JOHN 4

What Happened
Fletcher R. John, a director of ClearPoint Neuro, received an award of 662 shares on July 1, 2026. The shares were issued at $17.84 per share for a total value of $11,810 (transaction coded "A" for award/acquisition). This was a compensation-related issuance (payment of director fees), not an open-market purchase or sale.

Key Details

• Transaction date: July 1, 2026. Price used: $17.84 per share (total value $11,810). Footnote states the shares were issued at the issuer's closing common stock price on June 30, 2026.
• Transaction type/code: A = Award/Grant (acquisition as compensation).
• Shares owned after transaction: Not specified in the details you provided (see the SEC filing for the filer’s reported post-transaction holdings).
• Footnote: Shares issued under the issuer’s Seventh Amended and Restated 2013 Incentive Compensation Plan as payment of fees under the Non-Employee Director Compensation Plan.
• Filing timeliness: Form shows a filing date of July 6, 2026 for a July 1 transaction. Form 4s are typically due within two business days of the transaction; check the official SEC filing for any timeliness notation or explanation.

Context

• This was a compensation award to a non-employee director and is routine director pay rather than a market-driven buy or sell. Such grants are common and do not necessarily indicate the director’s personal market view.
• For retail investors, purchases (personal cash buys) often carry more interpretive weight than compensation awards; treat this as routine director compensation unless additional insider trades are reported.